New agents for invasive mycoses in children

被引:20
作者
Antachopoulos, C [1 ]
Walsh, TJ [1 ]
机构
[1] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA
关键词
invasine fungal infections; echinocandins; triazoles; Candida; Aspergillus; pediatrics;
D O I
10.1097/01.mop.0000150630.83442.e1
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose of review Invasive fungal infections are an important cause of morbidity and mortality in immunocompromised children of all ages. This review summarizes information on new antifungal agents, including current data on their clinical use in children, as well as alternative strategies such as antifungal combination and immunomodulation therapy. Recent findings Novel antifungal agents, such as the echinocandins and the second-generation triazoles, were recently introduced that exhibit promising efficacy against Candida spp., Aspergillus spp., and other opportunistic fungal pathogens. These compounds are generally well tolerated and show substantial efficacy as salvage treatment and equal or even superior efficacy compared with older azoles or amphotericin B as first-line or empiric therapy for fungal infections. Clinical studies of pharmacokinetics and efficacy of the new agents in the pediatric population are, however, limited. Summary the response rates observed with the recently introduced drugs, although superior in some cases compared with older antifungal agents, are still far from satisfactory. The development of new antifungal compounds as well as the use of alternative approaches of combination therapy and immunomodulation should be pursued through well-designed laboratory and clinical studies in pediatric patients.
引用
收藏
页码:78 / 87
页数:10
相关论文
共 132 条
[1]   Aspergillosis in children with cancer: A 34-year experience [J].
Abbasi, S ;
Shenep, JL ;
Hughes, WT ;
Flynn, PM .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (05) :1210-1219
[2]   Interferon-γ and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children [J].
Abzug, MJ ;
Walsh, TJ .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (08) :769-773
[3]   A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients [J].
Ally, R ;
Schürmann, D ;
Kreisel, W ;
Carosi, G ;
Aguirrebengoa, K ;
Dupont, B ;
Hodges, M ;
Troke, P ;
Romero, AJ .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1447-1454
[4]   In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model [J].
Andes, D ;
Marchillo, K ;
Stamstad, T ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1193-1199
[5]   Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis [J].
Andes, D ;
Marchillo, K ;
Conklin, R ;
Krishna, G ;
Ezzet, F ;
Cacciapuoti, A ;
Loebenberg, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :137-142
[6]   In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. [J].
Arikan, S ;
Lozano-Chiu, M ;
Paetznick, V ;
Rex, JH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :245-247
[7]  
Arikan Sevtap, 2002, Curr Opin Investig Drugs, V3, P555
[8]   Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy [J].
Baden, LR ;
Katz, JT ;
Fishman, JA ;
Koziol, C ;
DelVecchio, A ;
Doran, M ;
Rubin, RH .
TRANSPLANTATION, 2003, 76 (11) :1632-1637
[9]   Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans [J].
Barchiesi, F ;
Schimizzi, AM ;
Caselli, F ;
Giannini, D ;
Camiletti, V ;
Fileni, B ;
Giacometti, A ;
Di Francesco, LF ;
Scalise, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) :769-773
[10]   Infections diagnosed in the first year after pediatric stem cell transplantation [J].
Benjamin, DK ;
Miller, WC ;
Bayliff, S ;
Martel, L ;
Alexander, KA ;
Martin, PL .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (03) :227-234